Metacognitive Therapy Compared to Cognitive-behavioral Therapy

NCT07382323 | Not Yet Recruiting

• 1 other identifier: KI-2025-07875-02
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a qualitative study of participants who have taken part in a randomized controlled trial comparing transdiagnostic metacognitive therapy and disorder-specific cognitive-behavioral therapy for anxiety disorders. The purpose of the study is to explore participant perceptions of the respective treatment models to facilitate implementation and dissemination of the treatments.

Conditions

Generalized Anxiety Disorder; Social Anxiety Disorder; Posttraumatic Stress Disorder (PTSD)

Outcome Measures

Primary Outcomes (1)

• Qualitative interview data

  Participant responses based on questions posed in an interview

  Up to 13 weeks

Study Arms (2)

Transdiagnostic metacognitive therapy

EXPERIMENTAL

Metacognitive therapy in a transdiagnostic format; a single treatment protocol is used for all three anxiety disorders

Behavioral: Transdiagnostic metacognitive therapy

Disorder-specific cognitive-behavioral therapy

ACTIVE COMPARATOR

Cognitive-behavioral therapy in a disorder-specific format; each of the three anxiety disorders is treated using a separate treatment protocol

Behavioral: Disorder-specific cognitive-behavioral therapy

Interventions

Transdiagnostic metacognitive therapy BEHAVIORAL

Metacognitive therapy focuses on metacognitions.

Transdiagnostic metacognitive therapy

Disorder-specific cognitive-behavioral therapy BEHAVIORAL

Cognitive-behavioral therapy focuses on cognitions and/or behaviors.

Disorder-specific cognitive-behavioral therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or older,
• A principal diagnosis of generalized anxiety disorder, social anxiety disorder, or posttraumatic stress disorder,
• No change in dose during the last six weeks if on pharmacological treatment, and
• Ability to read and speak Swedish.

You may not qualify if:

• A current diagnosis of psychotic disorder, bipolar disorder, neurocognitive disorder, or moderate to severe substance use disorder,
• Acute suicide risk, or
• Concurrent psychological treatment.

Sponsors & Collaborators

• Karolinska Institutet: lead

MeSH Terms

Conditions

Generalized Anxiety Disorder; Phobia, Social; Stress Disorders, Post-Traumatic

Condition Hierarchy (Ancestors)

Anxiety Disorders; Mental Disorders; Phobic Disorders; Stress Disorders, Traumatic; Trauma and Stressor Related Disorders

Study Officials

• Benjamin Bohman

  Karolinska Institutet

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Benjamin Bohman

CONTACT

0701713443; benjamin.bohman@ki.se

Nathalie Petersén

CONTACT

0762082221; nathalie.petersen@ki.se

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: January 25, 2026
• First Posted: February 2, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: February 4, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share